Article Text

other Versions

Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination
  1. Philip C S de Whalley1,
  2. Matthew D Snape1,
  3. Emma Plested1,
  4. Ben Thompson1,
  5. Elizabeth Nuthall1,
  6. Omar Omar2,
  7. Ray Borrow3,
  8. Andrew J Pollard1
  1. 1Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK
  2. 2Centre for Statistics in Medicine, Wolfson College Annexe, Oxford, UK
  3. 3Vaccine Evaluation Unit, Manchester Medical Microbiology Partnership, Manchester, UK
  1. Correspondence to Dr Matthew Snape, Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LE, UK; matthew.snape{at}


Objectives To determine long-term seroprotection after serogroup C meningococcal (MenC) vaccination at the age of 9–12 years, with or without booster vaccination at the age of 13–15 years.

Design Observational cohort study; follow-on from randomised study.

Setting Participants were recruited from English secondary schools (in Oxfordshire and Buckinghamshire).

Participants and interventions Participants were primed with MenC CRM-glycoconjugate vaccine at the age of 9–12 years in the UK routine immunisation campaign. In previous studies they were randomised at 13 to 15 years of age to receive a booster dose of MenC-CRM glycoconjugate vaccine (CRM-group) or bivalent meningococcal serogroup A/C polysaccharide vaccine (PS-group), or they received no additional doses of MenC vaccine (control group). In this follow-on study, a blood sample was obtained 11 years after primary immunisation. Of 531 individuals eligible to participate, 134 were enrolled, and 124 were included in the analysis.

Main outcome measures MenC serum bactericidal antibody (SBA) geometric mean titre; proportion of participants with SBA titre ≥8 (putative protective threshold).

Results Median ages at priming, boosting and blood sampling were 10.61, 14.42 and 22.11 years, respectively. Geometric mean titres for MenC SBA were: CRM group 1373 (95% CI 954 to 1977); PS group 1024 (687 to 1526); and controls 284 (167 to 483). SBA titres ≥8 were present in 50/54 (92.6%) controls and 70/70 (100%) boosted individuals.

Conclusions The planned introduction in the UK of an adolescent booster of MenC conjugate vaccine in 2013 is likely to provide sustained protection against MenC disease.

Trial registration Registered on (NCT01459432).

  • Immunisation
  • Infectious Diseases

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.